GlassScriptPhysician profile
Abdullah Hanna-Moussa
NPI 1194735456
$2,346.35
in general payments reported to CMS, 2019-2025
26 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $264 · 2021: $602 · 2022: $246 · 2023: $192 · 2024: $565 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.70 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $457.45 | 2020-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $452.07 | 2019-2021 | |
| Corcept Therapeutics | $289.46 | 2021-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $195.13 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $171.28 | 2021-2024 | Minimed 780g |
| Amgen INC. | $157.78 | 2019-2025 | Tepezza, Repatha |
| Rhythm Pharmaceuticals, INC. | $124.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.71 | 2020-2023 | Tradjenta, Synjardy, Jardiance |
| Lilly USA, LLC | $52.49 | 2021-2022 | |
| Sequel Med Tech, LLC | $46.22 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $39.84 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $39.61 | 2024 | |
| Rgh Enterprises LLC | $28.22 | 2025 | |
| Amneal Pharmaceuticals LLC | $26.81 | 2022-2024 | Unithroid |
| Novartis Pharmaceuticals Corporation | $23.64 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.93 | 2019 | |
| Cequr Corporation | $21.80 | 2025 | Cequr Simplicity |
| Topcon Healthcare Solutions, INC. | $21.02 | 2019 | |
| Gilead Sciences, INC. | $19.42 | 2019 | |
| Globus Medical, INC. | $16.37 | 2025 | Omnia |
| Tandem Diabetes Care, INC. | $15.28 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $15.00 | 2024 | Ilet Bionic Pancreas |
| Amarin Pharma, INC. | $13.83 | 2021 | |
| Insulet Corporation | $13.12 | 2019 | |
| Intuity Medical INC | $13.01 | 2022 | |
| Medtronic Minimed, INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Hanna-Moussa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.